Panacea Venture

VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Eos BioInnovation is an investment firm focused on launching and building start-ups in the field of regenerative medicine. The company specializes in incubating, launching, and developing early-stage companies that emerge from leading academic labs and research institutions. By supporting these ventures, Eos BioInnovation aims to transform innovation in regenerative medicine and enable clients to achieve a strong track record of success.

Actym Therapeutics, Inc. is an immunotherapy company based in Berkeley, California, dedicated to the discovery and development of innovative therapies for cancer treatment. Founded in 2017, the company has developed a unique microbial-based immunotherapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy). This platform is designed to specifically target and enrich within various solid tumors while sparing healthy tissues. In preclinical studies, STACT has shown the capability to deliver multiplexed immuno-modulatory payloads directly to immune cells residing within tumors. This approach addresses significant challenges faced by conventional therapies, particularly systemic toxicities associated with intravenous dosing. By combining multiple payloads within a single therapy, STACT aims to engage various biological pathways, potentially enhancing treatment efficacy. Actym's commitment to overcoming the limitations of existing cancer therapies positions it as a promising player in the biopharmaceutical field.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Base Therapeutics is focused on developing innovative cell and gene editing technologies to address cancerous diseases. The company has created a natural killer cell genetic engineering platform, along with various cell therapy products aimed at treating several types of cancer, including lung cancer, liver cancer, glioma, and other hematological tumors. Through its advanced technologies, Base Therapeutics aims to enhance the safety and effectiveness of clinical applications of gene editing, both in vivo and in vitro, providing healthcare professionals with improved treatment options for patients suffering from these serious conditions.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Coastar Therapeutics is a biotechnology company based in San Diego, California, specializing in a novel erythrocyte enveloped virus delivery technology platform. This innovative platform enables repeated dosing of oncolytic viruses while evading immune system recognition, thereby addressing significant challenges associated with systemic and repeated administration of drug therapies. By utilizing human cell lipids that contain self-identifying motifs, Coastar's technology protects therapeutic viruses from neutralization by antibodies and immune cells, facilitating targeted delivery to tumor sites for effective cancer treatment and immunotherapy. The company was founded in 2017 and is focused on developing solutions not only for oncolytic viruses but also for other therapeutic applications, emphasizing cost-effective mass production and standardization of its products.

Jade Biomedical is a pioneering organization that specializes in regulatory and analytical testing services for biopharmaceutical companies globally. Recognized as the world's first registered biologics contract organization, Bio-CQOR, Jade Biomedical offers comprehensive quality management solutions tailored to the biopharmaceutical sector. The company provides a range of services, including contract quality, GMP testing, technical contracting, and inspection solutions. Its leadership team possesses extensive experience with major drug regulatory agencies such as NMPA, FDA, EMA, PMDA, and PICS, ensuring a deep understanding of the regulatory landscape. Jade Biomedical's expertise spans various therapeutic platforms, including monoclonal antibodies, antibody-drug conjugates, and advanced cell and gene therapies.

HanchorBio is a biotechnology research firm focused on developing innovative drugs for cancer treatment. The company specializes in drug discovery based on tumor immunology, with the goal of enhancing the quality of life for cancer patients. Through its research and development efforts, HanchorBio aims to revolutionize existing treatment paradigms and provide effective therapeutic options for those affected by cancer.

FineImmu is a biotechnology company specializing in the development of cell therapy drugs and immunodiagnostic products aimed at treating tumors. The company focuses on individualized tumor immunotherapy and precise combination therapies, which enhance the efficacy of treatments for common malignant tumors. FineImmu's innovative technology assesses the anti-tumor immune function and therapeutic effects of immune checkpoint inhibitors, including PD-1, PD-L1, and CTLA4. By providing healthcare professionals with effective tools for rapid efficacy assessment and tailored treatment options, FineImmu strives to improve patient outcomes in cancer care.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Harvest Integrated Research Organization (HiRO) is an innovative clinical research organization (CRO) with a global presence. It offers a comprehensive suite of services tailored for biotechnology and pharmaceutical companies, including pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, and end-to-end project management. HiRO is committed to facilitating the transition of pharmaceutical products from the laboratory to the market, collaborating closely with its clients to develop more effective and cost-efficient therapies for patients worldwide. As an emerging leader in the CRO sector, HiRO aims to enhance the drug development process through its integrated capabilities and dedication to quality.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

TaiLai Biosciences is a biotechnology company based in Shanghai, China, focused on advancing cancer research through innovative multiomics technology. The company specializes in the development of non-invasive cancer screening and analysis tools, which allow researchers to gain deeper insights into cancer development and facilitate the creation of immune-guided therapies. TaiLai Biosciences offers a range of biopsy products and services that leverage proprietary biomultiomics technology, integrating extensive biological data, including DNA, RNA, proteins, and metabolites. By employing bioinformatics and computational science, the company aims to uncover correlations within this vast information, contributing to improved cancer diagnostics and treatment options.

VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Maestro Surgical is a technology company specializing in medical surgical robotics. It develops advanced motion control technology chipsets, designed to deliver real-time performance, synchronization, and miniaturization. The company's platform integrates proprietary medical image processing algorithms, facilitating efficient collection and utilization of X-ray data in the medical sector.

Innovative Rehabilitation Equipment Company that Helps Mobility-Impaired Patients to Regain Walking Ability

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

XW Laboratories Inc. is a biopharmaceutical company based in Wuhan, China, specializing in the development of innovative treatments for neurological disorders. Founded in 2014, the company has established three distinct research and development platforms, including Prodrug and Functional Group Switch, which facilitate the rapid identification of novel drug candidates while minimizing development costs and time. The company is committed to creating medications that enhance patient compliance and reduce toxicity. Additionally, XW Laboratories is advancing its capabilities in immunoneurology through a mitochondria-targeting platform. While primarily focused on the Chinese market, the company also engages in collaborations to reach foreign markets, aiming to transform the quality of life for patients suffering from neurological conditions.

XWPharma is a biotechnology company based in the Bay Area, California, focused on developing novel therapeutics for underserved central nervous system (CNS) disorders. Their primary areas of interest include sleep disorders like insomnia and neuropsychiatric conditions. The company specializes in drug discovery to address these neglected illnesses, aiming to improve patients' lives by enabling them to overcome sleep-related challenges and lead healthier lives.

Actym Therapeutics, Inc. is an immunotherapy company based in Berkeley, California, dedicated to the discovery and development of innovative therapies for cancer treatment. Founded in 2017, the company has developed a unique microbial-based immunotherapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy). This platform is designed to specifically target and enrich within various solid tumors while sparing healthy tissues. In preclinical studies, STACT has shown the capability to deliver multiplexed immuno-modulatory payloads directly to immune cells residing within tumors. This approach addresses significant challenges faced by conventional therapies, particularly systemic toxicities associated with intravenous dosing. By combining multiple payloads within a single therapy, STACT aims to engage various biological pathways, potentially enhancing treatment efficacy. Actym's commitment to overcoming the limitations of existing cancer therapies positions it as a promising player in the biopharmaceutical field.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

TriArm Therapeutics is a cell therapy company that specializes in developing cellular immunotherapy products aimed at treating cancer patients. It was established by Panacea Venture and conducts research and development operations across Germany, the United States, and the Greater China region. The company's primary focus is on the research and clinical application of its CD19 CAR-T product, utilizing non-viral gene transfer technology. This innovative approach significantly lowers the costs and reduces the time required for preparing cell therapy products, ultimately enhancing the effectiveness of tumor treatments.

Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Tactiva Therapeutics, LLC is an immuno-oncology company based in Buffalo, New York, specializing in the development of innovative cancer immunotherapies. Founded in 2016, the company focuses on adoptive cell therapy, employing a dual T cell receptor approach that utilizes engineered CD4 and CD8 T cells. This platform aims to generate a durable supply of CD4 cells that exhibit direct anti-tumor activity while also providing sustained helper functions to CD8 T cell-derived effector T cells. Through its advanced therapeutic strategies, Tactiva Therapeutics seeks to enhance the diagnosis and treatment of cancer, addressing the needs of patients with life-threatening diseases.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

BioGraph 55 is an immuno-oncology target discovery and drug development company focused on addressing significant unmet clinical needs in oncology and autoimmunity. The company specializes in discovering and developing bispecific antibodies for these areas using a reverse translational approach. This involves identifying potential cellular targets within diseased tissues and validating mechanisms to capture clinically relevant content from the tumor microenvironment, thereby advancing novel B-cell therapies.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.